Caribou Biosciences (NASDAQ:CRBU) Announces Earnings Results

Caribou Biosciences (NASDAQ:CRBU) issued its earnings results on Wednesday. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06, Zacks reports. The firm had revenue of $2.02 million for the quarter, compared to analyst estimates of $3.37 million. Caribou Biosciences had a negative return on equity of 43.47% and a negative net margin of 1,290.81%.

Caribou Biosciences Trading Down 3.6 %

Shares of CRBU traded down $0.10 during midday trading on Friday, reaching $2.68. The stock had a trading volume of 2,467,955 shares, compared to its average volume of 1,257,875. The company has a market capitalization of $242.16 million, a price-to-earnings ratio of -1.62 and a beta of 2.26. The company’s 50-day moving average is $2.01 and its 200 day moving average is $2.30. Caribou Biosciences has a 12-month low of $1.50 and a 12-month high of $8.33.

Analysts Set New Price Targets

A number of research analysts have weighed in on CRBU shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $14.00 target price on shares of Caribou Biosciences in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a research note on Tuesday, September 3rd.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.